Retatrutide 20mg
Retatrutide 20mg
Retatrutide 20mg
Often called simply "reta" in research communities, retatrutide is a triple receptor agonist (GIP / GLP-1 / glucagon) currently in Phase 3 development — this is our most popular 20mg research vial.
Retatrutide 20mg is supplied as a lyophilised research material intended exclusively for laboratory research applications.
Each vial contains 20mg of lyophilised material in a sealed glass research vial and is supplied for research use only.
![]()
Product Information![]()
Product: Retatrutide
Quantity: 20mg
Form: Lyophilised Powder
Appearance: White to off-white lyophilised cake
Container: Sealed glass research vial
Storage: Store refrigerated at 2–8°C before reconstitution.
Intended Use: Research Use Only.
Third-Party Lab Verification (COA)
Independently tested by Bioviridian Inc., issued via Purity Analytics (digitally signed COA, batch 20260105L0KA2RS20).
| Sample tested | Aug 2026 |
| Identity (LC-MS) | Confirmed |
| Purity (HPLC-UV) | 99.76% |
| Net content | 20.18 mg (20 mg label claim) |
View full certificate of analysis · Verify at verify.purityanalytics.com